--- canonical_name: Dihexa alternate_names: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408 canonical_topic: Dihexa for Cognitive Enhancement short_topic_lc: dihexa_cognition creation_date: 2026-0704-0208 creator_ai_fullname: Opus 4.8 --- # Dihexa for Cognitive Enhancement

Evidence Review created on 07/04/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408 ## Motivation Dihexa is a small synthetic peptide (a short chain of protein building blocks) first made in a university laboratory to treat memory loss. It is a chemically stabilized relative of a natural body signal called angiotensin, redesigned so it survives digestion, enters the brain, and lasts long enough to act. Rather than nudging brain chemistry the way a stimulant does, it is thought to switch on a growth-factor system that prompts brain cells to build new connections — the physical basis of learning and memory. The compound drew attention because, in animal experiments, it restored memory in impaired rodents at very low doses taken by mouth. That result fueled interest from Alzheimer's researchers and, separately, from a self-experimentation community that now buys the peptide from unregulated suppliers as a "smart drug." No human trials of dihexa have ever been completed, and the same growth pathway it stimulates is one that tumors exploit to grow. This review examines what is actually known about dihexa for cognitive enhancement: how it is thought to work, what the animal evidence shows, where the safety concerns lie, and how far the current data can and cannot be stretched toward use in people. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level, directly relevant sources that give an overview of dihexa and the growth-factor system it targets. * [Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents](https://pubmed.ncbi.nlm.nih.gov/23055539/) - McCoy et al., 2013 The foundational paper describing the synthesis of dihexa and its ability to reverse memory deficits in rodents at low oral doses, establishing the compound's procognitive profile. * [The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/25649658/) - Wright & Harding, 2015 A narrative review by the originating researchers explaining why the growth-factor system dihexa engages is considered a therapeutic target, useful for understanding the intended mechanism and rationale. * [AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway](https://pubmed.ncbi.nlm.nih.gov/34827486/) - Sun et al., 2021 An independent group's replication showing dihexa improved memory in a genetic mouse model of Alzheimer's disease, adding external support beyond the originating laboratory. * [Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats](https://pubmed.ncbi.nlm.nih.gov/38489193/) - Wells et al., 2024 A recent primary study extending dihexa research into a neurodegeneration model beyond Alzheimer's, illustrating both the breadth of preclinical interest and the continued absence of human data. Only four sources are listed. None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) have covered dihexa, and the list has not been padded with commercial peptide-seller pages that fail the quality bar. ## Grokipedia * [Dihexa](https://grokipedia.com/page/Dihexa) A comprehensive encyclopedia entry covering dihexa's chemical identity, proposed mechanism, preclinical research history, and its status as an experimental compound, providing a useful high-level orientation to the topic. ## Examine No Examine article exists for dihexa. Examine focuses on dietary supplements and nutrients supported by human research and does not cover experimental, research-only peptides that lack human clinical data. ## ConsumerLab No ConsumerLab article exists for dihexa. ConsumerLab independently tests commercially marketed supplements and does not cover experimental research peptides, which are not sold as regulated consumer supplements. ## Systematic Reviews This section lists the systematic review evidence identified for dihexa and its parent compound class on PubMed. * [Cognitive Benefits of Angiotensin IV and Angiotensin-(1-7): A Systematic Review of Experimental Studies](https://pubmed.ncbi.nlm.nih.gov/29733881/) - Ho & Nation, 2018 A systematic review of animal experiments examining the memory effects of angiotensin IV and related peptides, including dihexa, concluding that these compounds consistently improve cognition in preclinical models while noting the complete absence of human trials. ## Mechanism of Action Dihexa is a metabolically stabilized analog of angiotensin IV (Ang IV, a short peptide fragment of the blood-pressure hormone system). Its cognitive effects are attributed to potentiation of the hepatocyte growth factor / c-Met system (HGF is a signaling protein; c-Met, short for mesenchymal-epithelial transition factor, is the receptor it binds — together they drive cell growth, survival, and, in the brain, the formation of new synapses). * **Primary pathway:** Dihexa is thought to bind HGF and stabilize its active dimer form, amplifying signaling through the c-Met receptor. Activated c-Met triggers two downstream cascades — the PI3K/AKT pathway (phosphoinositide 3-kinase/protein kinase B, which promotes cell survival) and the ERK/MAPK pathway (extracellular signal-regulated kinase, which drives growth signals) — leading to dendritic spine formation and synaptogenesis (growth of new connections between neurons). * **Competing mechanistic accounts:** The compound was originally proposed to act at the AT4 receptor, identified as insulin-regulated aminopeptidase (IRAP, an enzyme that breaks down peptides). Later work by Benoist and colleagues reported that dihexa's procognitive and synapse-building effects are abolished when c-Met is blocked, indicating the HGF/c-Met system — not IRAP inhibition alone — is required; however, that 2014 paper has since been retracted, so this specific dependence claim should be treated with caution. Both accounts appear in the literature, and the HGF/c-Met system remains the more widely favored explanation, though the mechanistic evidence is not settled. * **Reported potency:** In cell-based synaptogenesis assays, dihexa is active at sub-picomolar to picomolar concentrations, which underlies the widely repeated marketing claim that it is "seven orders of magnitude more potent than BDNF" (brain-derived neurotrophic factor, the brain's principal growth factor). This comparison reflects in-vitro assay potency, not a demonstrated real-world superiority, and is frequently overstated. Key pharmacological properties are only partly characterized: * **Selectivity:** Acts on the HGF/c-Met system rather than binding c-Met directly as an agonist; not a classical receptor agonist. * **Half-life and metabolism:** Human pharmacokinetics have never been formally characterized. Dihexa was deliberately engineered for metabolic stability — an N-terminal hexanoic acid cap and a C-terminal amide protect it from aminopeptidases — which confers oral activity and resistance to rapid breakdown in preclinical models. As a small peptide it is not expected to be a major substrate of cytochrome P450 enzymes (e.g., CYP3A4). * **Tissue distribution:** Lipophilic and blood-brain-barrier penetrant, allowing central nervous system access after oral administration in animals. ## Historical Context & Evolution * **Original intended use:** Dihexa was developed in the laboratory of Joseph Harding and John (Jay) Wright at Washington State University in the early 2010s as a candidate treatment for Alzheimer's disease and other dementias. The goal was to convert the pro-cognitive but unstable natural peptide angiotensin IV into an orally active, metabolically stable drug. * **Why it came to be considered for cognitive enhancement:** After McCoy and colleagues reported in 2013 that dihexa reversed memory deficits in rodents at low oral doses, and Benoist and colleagues proposed the synapse-building mechanism in 2014 (a paper later retracted), the compound attracted attention beyond dementia research. Its combination of oral activity, brain penetration, and dramatic in-vitro potency led a self-experimentation and "biohacking" community to adopt it as a nootropic (cognitive enhancer), sourced from research-chemical suppliers. * **What the historical research actually found:** The primary studies described genuine, reproducible memory restoration in scopolamine-amnesia, aged, and lesioned rodents, plus robust synaptogenesis in cultured neurons. These are legitimate findings within their preclinical scope, not fringe claims. * **Evolution of scientific opinion:** The originating group co-founded a company (M3 Biotechnology, later Athira Pharma) to develop the approach. Notably, the clinical program advanced a different, proprietary small molecule (fosgonimeton / ATH-1017) rather than dihexa itself, and dihexa never entered human trials. Enthusiasm has been tempered by a recognized concern — the same HGF/c-Met system is exploited by tumors — and by the later failure of the related clinical candidate to meet its primary endpoint in a large Alzheimer's trial. The current standing is that the mechanism remains scientifically interesting while human efficacy and safety for dihexa remain entirely unestablished. ## Expected Benefits The evidence for dihexa's benefits derives almost entirely from animal and cell studies; no benefit has been confirmed in humans. Grades below reflect that ceiling. ### Low 🟩 #### Restoration of Memory in Animal Models of Cognitive Impairment Across multiple rodent models — scopolamine-induced amnesia, aged animals, and lesion or genetic Alzheimer's models — orally administered dihexa restored learning and memory toward normal, most often measured in the Morris water maze (a spatial-memory swim test). The effect has been reported by the originating laboratory and independently replicated (e.g., Sun et al., 2021 in APP/PS1 mice), strengthening internal consistency. The limitation is fundamental: these are animal disease models, and no controlled human data exist, so relevance to a healthy person seeking enhancement is unestablished. **Magnitude:** In rodent spatial-memory tasks, dihexa restored performance from an impaired state to near that of unimpaired controls at oral doses of roughly 1–2 mg/kg; no human effect size exists. #### Promotion of Synaptogenesis and Neuroplasticity In cultured hippocampal neurons, dihexa increases dendritic spine density and the number of functional synapses through the HGF/c-Met system, providing a plausible structural basis for the memory findings. This is among the best-characterized aspects of the compound mechanistically. However, the translation from dish to living human brain is unproven, and the frequently cited comparison to BDNF reflects assay potency rather than demonstrated clinical benefit. **Magnitude:** Synaptogenic activity is reported at sub-picomolar to picomolar concentrations in vitro, with measurable increases in spine density; no in-vivo human magnitude is available. ### Speculative 🟨 #### Cognitive Enhancement in Healthy Individuals The core reason the compound is marketed as a nootropic — improved memory, focus, or learning in people without cognitive impairment — rests entirely on mechanistic extrapolation and unverified anecdotal user reports. No controlled study has tested dihexa in healthy humans, and animal benefits were demonstrated against a backdrop of impairment, which does not predict enhancement of already-normal cognition. #### Neuroregeneration and Recovery After Nerve or Brain Injury Preliminary animal work suggests dihexa may aid functional recovery after peripheral nerve damage and in other neurodegeneration models (e.g., a Huntington's disease-like rat model), consistent with its growth-promoting mechanism. The basis is a small number of isolated preclinical reports with no human confirmation. #### Disease Modification in Alzheimer's and Other Neurodegenerative Disease Because dihexa reduced markers of pathology and improved cognition in animal Alzheimer's models, it is proposed as potentially disease-modifying. This remains speculative: dihexa itself was never trialed in humans, and the related clinical-stage molecule targeting the same pathway did not meet its primary endpoint in a pivotal Alzheimer's study. ## Benefit-Modifying Factors Because human data are absent, the following are inferred from the mechanism and the parent compound class rather than demonstrated in people. * **Baseline cognitive status:** Animal benefits were most pronounced against an impaired baseline (chemical amnesia, aging, lesions). Individuals with existing cognitive decline are, in principle, more likely to show a measurable effect than those with normal cognition, for whom benefit is least supported. * **Genetic polymorphisms:** Variation in the *MET* gene (encoding the c-Met receptor) and in HGF signaling components could theoretically alter responsiveness, since the mechanism depends on this system. APOE4 carriers (the strongest common genetic risk factor for Alzheimer's) represent a population of research interest, though no dihexa data stratified by genotype exist. * **Age:** Aged rodents were a key responsive population, and older adults at the upper end of the target range — where synaptic loss is greater — are the group for whom the mechanism is most relevant; they are also the group with the highest baseline cancer risk, complicating the risk-benefit balance. * **Baseline biomarker levels:** No validated biomarker predicts response. Endogenous HGF and growth-factor tone could plausibly modify effect but have not been studied in this context. * **Sex-based differences:** Preclinical studies have not systematically compared sexes, and no sex-specific efficacy data are available for dihexa. * **Pre-existing health conditions:** Neurodegenerative disease was the modeled context; whether metabolic, vascular, or inflammatory comorbidities modify response is unknown. ## Potential Risks & Side Effects No human safety data exist for dihexa. The risks below combine documented mechanistic concerns with the hazards inherent to an unregulated research chemical. Grades reflect the absence of clinical data. ### Low 🟥 #### Product Contamination, Mislabeling, and Dosing Errors Dihexa is sold only as a research chemical by unregulated suppliers, with no pharmaceutical quality control. Independent testing of the broader gray-market peptide sector has repeatedly found products that are underdosed, overdosed, degraded, or contaminated with solvents, bacterial endotoxin, or incorrect compounds. Users reconstitute and dose these products themselves, adding measurement error. This is the most concrete, present-day hazard because it applies to every real-world purchase regardless of the molecule's intrinsic effects. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Cancer Promotion via HGF/c-Met Pathway Activation The mechanism dihexa exploits is a recognized driver of cancer: HGF/c-Met signaling promotes tumor cell proliferation, survival, invasion, angiogenesis, and metastasis, and c-Met is a well-established proto-oncogene. Chronically amplifying this system throughout the body could, in principle, accelerate the growth of existing or occult tumors. No study has measured cancer outcomes with dihexa, so this remains a theoretical but mechanistically serious concern — arguably the single most important reason for caution, particularly with prolonged use or in individuals with cancer risk. #### Unknown Human Safety Profile and Absence of Clinical Trial Data Dihexa has never completed a human clinical trial of any phase, so there is no established safe dose, no documented adverse-event profile, no drug-interaction data, and no information on long-term consequences. Every human use is effectively uncontrolled self-experimentation. #### Pathological Angiogenesis and Tissue Fibrosis Beyond oncogenesis, HGF/c-Met activation can promote new blood-vessel growth and, in some tissues, fibrosis (scarring). Sustained systemic stimulation could theoretically aggravate conditions involving abnormal vascular growth (for example proliferative retinal disease) or fibrotic processes, though no clinical evidence addresses this for dihexa. #### Overstimulation, Headache, and Neurological Effects Anecdotal user reports describe headaches, irritability, brain fog, or a sense of overstimulation, plausibly related to growth-factor signaling or to impurities. These reports are uncontrolled, unverified, and cannot be attributed to dihexa itself with any confidence. ## Risk-Modifying Factors As with benefits, these factors are inferred from mechanism and general pharmacology rather than demonstrated for dihexa in humans. * **Personal or family history of cancer:** Given the HGF/c-Met oncogenic concern, individuals with active cancer, a history of cancer, or strong hereditary cancer risk represent the group in whom the theoretical harm is greatest. * **Genetic polymorphisms:** Germline variants that increase c-Met activity or cancer susceptibility (for example hereditary cancer syndromes, or *MET* amplification-prone contexts) could plausibly heighten risk. No dihexa-specific pharmacogenetic data exist. * **Age:** Older adults carry higher baseline prevalence of undetected malignancy and vascular disease, so the same pathway stimulation may carry greater downside at the upper end of the target range. * **Pre-existing health conditions:** Conditions involving abnormal tissue proliferation, fibrosis, or angiogenesis (e.g., pulmonary fibrosis, proliferative retinopathy) are theoretical grounds for heightened caution. * **Baseline biomarker levels:** No biomarker is validated to stratify risk; elevated tumor markers or unexplained abnormalities would be reasons for concern before any use. * **Sex-based differences:** No sex-specific safety data are available for dihexa. ## Key Interactions & Contraindications Formal interaction data do not exist for dihexa; the following are mechanistic and precautionary. * **Prescription drug interactions:** No documented interactions. Theoretically, c-Met inhibitors used in oncology (e.g., crizotinib, cabozantinib, capmatinib) would act in direct opposition to dihexa's mechanism, and concurrent use is nonsensical and contraindicated in that clinical setting. * **Over-the-counter medication interactions:** None documented. No specific OTC interaction is established. * **Supplement interactions:** None documented. Supplements marketed to raise growth-factor or neurotrophic signaling (e.g., certain "BDNF-boosting" stacks) could theoretically add to growth-pathway stimulation, but this is unquantified. * **Additive-effect substances:** Other experimental growth-factor-potentiating or synaptogenic peptides could, in principle, compound the same HGF/c-Met or neurotrophic signaling; no data confirm additive risk or benefit. * **Other intervention interactions:** Combined use with other unregulated research peptides (a common "stacking" practice) multiplies the uncertainty and contamination risk without any supporting evidence. * **Severity and consequence:** Because no interaction is characterized, all combinations should be treated as caution-level or higher by default; the clinical consequence of greatest concern is unmonitored stimulation of a cancer-associated pathway. * **Mitigating actions:** Where any use occurs, avoiding co-administration with other growth-pathway agents and separating it from oncologic therapy are the only sensible precautions; no validated dose-adjustment or timing protocol exists. * **Populations who should avoid this intervention:** Anyone with active or prior cancer, a strong hereditary cancer predisposition, pregnancy or breastfeeding (no reproductive safety data), individuals under 18, and those with proliferative or fibrotic disease. Given the complete absence of human safety data, no population can be identified for whom use is clearly safe. ## Risk Mitigation Strategies * **Cancer risk screening before any consideration:** Because the dominant concern is HGF/c-Met-driven tumor promotion, age-appropriate cancer screening and a thorough personal and family cancer history are the logical first step, and active or prior malignancy is a reason not to use dihexa at all — this mitigates the pathway's central oncogenic risk. * **Third-party purity and identity testing:** Since contamination and mislabeling are the most concrete hazards, obtaining an independent certificate of analysis (identity, purity ≥98%, and endotoxin testing) for any batch mitigates the risk of dosing an incorrect or contaminated compound; without such testing the product content is unknown. * **Conservative, time-limited exposure:** Limiting any exposure to short durations rather than continuous long-term use reduces cumulative stimulation of a growth-associated pathway, addressing the theoretical concern that chronic activation is more likely to promote tumor growth. * **Avoid stacking with other growth-pathway agents:** Not combining dihexa with other experimental peptides or neurotrophic "boosters" limits compounded, unquantified stimulation of the same signaling systems and reduces contamination exposure from multiple gray-market sources. * **Medical supervision and baseline labs:** Undergoing baseline bloodwork and, ideally, physician oversight before and during any use provides a chance to detect adverse changes early, mitigating the risk posed by the complete absence of an established human safety profile. ## Therapeutic Protocol There is no validated human protocol for dihexa. The intervention has never been through human trials, and the details below describe what preclinical work used and what unregulated users report — presented for completeness, not as a usable regimen. * **Standard protocol from research:** No clinical protocol exists. Preclinical efficacy in rodents was achieved with oral or injected doses on the order of 1–2 mg/kg; leading academic work (the Harding/Wright laboratory at Washington State University) never translated this into a human dosing schedule. * **Competing approaches:** The originating group's own translational path deliberately moved to a different, proprietary molecule (fosgonimeton) for human development rather than dihexa; the "biohacker" approach of self-dosing raw dihexa is a separate, unsanctioned practice. Neither is framed here as a default, and only the former was ever subjected to formal drug development. * **Expert or clinic that popularized each approach:** The academic HGF/c-Met approach traces to Joseph Harding and John Wright; the nootropic self-experimentation use has no legitimate clinical sponsor and is popularized chiefly by peptide vendors and online communities. * **Best time of day:** Not established; no chronobiological data exist for dihexa. * **Half-life consideration:** Human half-life is uncharacterized; the molecule was engineered for metabolic stability and oral activity, but this does not translate into a known dosing interval for people. * **Single vs. split dosing:** Not established; anecdotal users variously report once-daily oral or transdermal use, but no evidence supports any particular schedule. * **Genetic considerations:** No pharmacogenetic guidance exists; variants in the c-Met/HGF system are of theoretical interest only. * **Sex-based differences:** No sex-specific dosing data are available. * **Age considerations:** No age-adjusted dosing exists; older adults face both greater potential relevance and greater theoretical cancer risk. * **Baseline biomarkers:** No biomarker is used to guide dosing. * **Pre-existing conditions:** No condition-specific protocol exists; cancer history is a reason to avoid rather than adjust. ## Discontinuation & Cycling * **Lifelong vs. short-term:** No evidence supports any duration. Given the growth-pathway safety concern, indefinite continuous use is the least defensible pattern, and there is no established therapeutic course. * **Withdrawal effects:** None are documented. As dihexa is not known to act on classical neurotransmitter or receptor-dependence systems, physical withdrawal is not an established phenomenon, but this is unstudied. * **Tapering:** No tapering protocol exists or has been studied; there is no evidence that gradual discontinuation is necessary. * **Cycling:** Whether cycling preserves any effect is unknown. Some users self-impose on/off cycles on the theory that this limits cumulative pathway stimulation, but no efficacy or safety data support cycling for dihexa. * **Practical framing:** Because benefit in humans is unproven and the main safety concern scales with cumulative exposure, the discontinuation question is dominated by risk minimization rather than by any withdrawal or maintenance-of-effect consideration. ## Sourcing and Quality * **Regulatory and supply status:** Dihexa is not an approved drug or a dietary supplement anywhere; it is sold only as a "research chemical" or "for research use only" peptide, meaning no regulator verifies its identity, purity, or safety. * **What to look for:** Because product quality is the most concrete risk, any material should carry a batch-specific third-party certificate of analysis documenting identity (mass spectrometry), purity (typically ≥98% by high-performance liquid chromatography), and endotoxin/sterility testing; absence of such documentation should be treated as an unknown product. * **Formulation considerations:** Dihexa is supplied variously as a raw powder, an oral solution, or a transdermal cream; the transdermal route in particular has no human absorption data, so delivered dose is highly uncertain across formulations. * **Reputable brands or pharmacies:** There are no reputable pharmaceutical manufacturers or compounding pharmacies producing dihexa for human use; it is not a recognized compounding ingredient, and all consumer sources are unregulated research-chemical suppliers whose reliability cannot be assured. * **Bottom line on sourcing:** The combination of no legitimate manufacturer, no regulatory oversight, and documented gray-market quality problems means sourcing risk cannot be reduced to an acceptable level through brand selection alone. ## Practical Considerations * **Time to effect:** Not established in humans. In rodent studies, cognitive improvements were measured over days of dosing; any human timeline is unknown and anecdotal claims of rapid effects are unverified. * **Common pitfalls:** Over-relying on the in-vitro "more potent than BDNF" marketing claim; assuming animal memory-rescue predicts enhancement in healthy people; ignoring the cancer-pathway concern; and trusting unlabeled product potency, leading to unintended over- or under-dosing. * **Regulatory status:** Dihexa is unapproved for human use; it is neither an FDA-approved drug nor a lawful dietary supplement, and it is sold under "research use only" labeling. Personal use exists in a legal gray area and outside any medical framework. * **Cost and accessibility:** Dihexa is comparatively expensive per gram and is accessible only through research-chemical vendors, with no insurance coverage and no pharmacy channel; supply reliability and product consistency are poor. * **Overall practicality:** As a practical matter, dihexa is an experimental compound with no established human dose, no quality assurance, and a serious unresolved safety question, which together place it far outside routine, responsible use. ## Interaction with Foundational Habits * **Sleep:** Interaction is indirect and unstudied. There is no evidence dihexa disrupts or improves sleep architecture; anecdotal reports of overstimulation or headache could plausibly interfere with sleep in some users, but no mechanism or study confirms a direct effect, and no timing guidance can be given. * **Nutrition:** Interaction is indirect and unstudied. No dietary pattern is known to enhance or blunt dihexa, and no nutrient depletion is documented. As a peptide taken orally, food effects on its uncertain absorption are unknown; no foods to include or avoid are established. * **Exercise:** Interaction is indirect and theoretically potentiating. Physical exercise independently raises endogenous growth and neurotrophic factors (including BDNF) and supports synaptic health, so exercise plausibly overlaps with dihexa's intended pathway; however, no study has examined combined effects, and exercise is the far better-evidenced route to the same cognitive goal. * **Stress management:** Interaction is indirect and unstudied. Chronic stress suppresses neurotrophic signaling and neuroplasticity, so stress reduction is directionally complementary to dihexa's mechanism, but there is no evidence dihexa alters cortisol or the stress response, and no practical combined protocol exists. ## Monitoring Protocol & Defining Success Given the absence of human data and the cancer-pathway concern, monitoring would be precautionary and centered on early detection of harm rather than on confirming benefit. Baseline testing before any use should establish general health and screen for contraindications. Baseline testing should be completed before any use and reviewed with a physician; ongoing monitoring, if any use occurs, would reasonably be repeated at roughly 4–8 weeks and then every 3–6 months, alongside age-appropriate cancer screening on its standard schedule. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Complete blood count (CBC) | Within standard reference range | Detects unexplained cytopenias or abnormalities before/after use | Baseline then periodic; abnormalities warrant stopping and evaluation | | Comprehensive metabolic panel (CMP) | Fasting glucose 70–90 mg/dL; liver enzymes ALT/AST < 25 U/L | Screens general organ function, including liver where peptides are processed | Fasting sample preferred; conventional ALT/AST upper limits (~40 U/L) are higher than the functional target | | High-sensitivity C-reactive protein (hs-CRP) | < 1.0 mg/L | General marker of systemic inflammation; unexplained rises merit attention | Avoid testing during acute illness; pair with baseline health review | | Age-appropriate cancer screening | Per established screening guidelines | Central precaution given the HGF/c-Met tumor-promotion concern | Not a blood value; includes standard screenings for age/sex; a prior cancer history is a reason to avoid entirely | Qualitative markers that users might track: * Subjective memory, recall, and learning ease * Mental clarity versus brain fog or overstimulation * Headache frequency or new neurological symptoms * Energy and mood stability * Any new or changing lumps, skin lesions, or unexplained symptoms warranting prompt medical review ## Emerging Research * **No dihexa human trials registered:** As of July 2026, a search of ClinicalTrials.gov returns no registered clinical trials of dihexa itself in any condition, underscoring that all human use remains outside formal research. * **HGF/c-Met clinical proxy — fosgonimeton (ATH-1017):** The clinical test of dihexa's pathway advanced through a related, distinct small molecule. The Phase 2/3 LIFT-AD trial in mild-to-moderate Alzheimer's disease ([NCT04488419](https://clinicaltrials.gov/study/NCT04488419), ~554 participants) evaluated fosgonimeton; its publicly reported topline result did not meet the primary cognitive endpoint for monotherapy, a finding that weakens the near-term clinical case for the mechanism. * **Terminated dementia programs:** Companion studies of the same molecule, including an open-label Alzheimer's study ([NCT04886063](https://clinicaltrials.gov/study/NCT04886063)) and the SHAPE trial in Parkinson's disease dementia and dementia with Lewy bodies ([NCT04831281](https://clinicaltrials.gov/study/NCT04831281)), were terminated, reflecting a contraction of the clinical program. * **Independent preclinical replication (strengthening direction):** Work such as [Sun et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34827486/) reproduced dihexa's memory benefits in a genetic Alzheimer's mouse model outside the originating laboratory, and [Benoist et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25187433/) reported the HGF/c-Met dependence of the effect — though this paper has since been retracted, which weakens rather than strengthens the mechanistic case and underscores the need for independent confirmation. * **Broadening indications (uncertain direction):** Recent primary studies extend dihexa into peripheral nerve repair ([Weiss et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34703584/)) and Huntington's-like models ([Wells et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38489193/)); these expand the mechanistic story but do not address human cognitive enhancement. * **Key open questions that could change understanding:** Direct human pharmacokinetic and safety data for dihexa; long-term carcinogenicity testing given the HGF/c-Met concern; and any controlled trial in healthy people — none of which currently exist. Future evidence on the cancer question in particular could substantially strengthen or weaken the case for any human use. ## Conclusion Dihexa is an experimental peptide, first built to treat memory loss, that is thought to work by switching on a growth-signal system in the brain to spur new connections between nerve cells. In animals, it reliably restored memory in impaired rodents at low oral doses, and it builds new nerve-cell connections powerfully in laboratory dishes. That preclinical record is genuine and has been repeated by more than one research group. The evidence base, however, is almost entirely from animals and cells. No completed human trial exists, so there is no established dose, no safety record, and no confirmation that a healthy person's thinking would improve at all. Two concerns weigh heavily. First, the same growth system dihexa stimulates is one that tumors use to grow, making long-term or whole-body stimulation a real theoretical hazard. Second, the compound is sold only through unregulated suppliers, so what a buyer actually receives is uncertain. Where the science is strongest — memory rescue in animals and connection-building in the lab — it is also furthest from proving anything about people. The current picture is a mechanistically intriguing compound whose promise remains unproven and whose most serious safety question is unresolved. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**